U.S. regulators OK Alzheimer's drug developed by Japan's Eisai
Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
- Product Code
- ILEA001224079
- Registered date
- 2023/1/07 00:00:00
- Credit
- Kyodo / Kyodo News Images
- Media source
- 2023 Kyodo News
- Media size
- 3775 × 2806 pixel
- Deployment size
- 563.80(KB)*
*File size when opened in Photoshop, etc.